1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Midatech Pharma plc
  6. News
  7. Summary
    MTPH   GB00BKT14T00

MIDATECH PHARMA PLC

(MTPH)
  Report
Delayed London Stock Exchange  -  05/25 11:35:20 am EDT
9.750 GBX    0.00%
12:58pMIDATECH PHARMA : Notice of 2022 AGM
PU
05/17European ADRs Move Higher in Tuesday Trading
MT
05/05European ADRs Decline in Thursday Trading
MT
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Midatech Pharma, Janssen Extend R&D Partnership On Experimental Medicine

01/17/2022 | 03:02am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON -0.91% 179.79 Delayed Quote.6.04%
MIDATECH PHARMA PLC 0.00% 9.75 Delayed Quote.-46.58%
ON SEMICONDUCTOR CORPORATION 2.51% 55.87 Delayed Quote.-19.76%
All news about MIDATECH PHARMA PLC
12:58pMIDATECH PHARMA : Notice of 2022 AGM
PU
05/17European ADRs Move Higher in Tuesday Trading
MT
05/05European ADRs Decline in Thursday Trading
MT
04/26Earnings Flash (MTPH.L) MIDATECH PHARMA Posts FY21 Revenue GBP578,000
MT
04/26Midatech Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/14Midatech Pharma Gets Nasdaq Non-Compliance Notification
MT
04/14MIDATECH PHARMA : Receipt of NASDAQ Notice - Form 6-K
PU
04/14Midatech Pharma Gets Nasdaq Non-Compliance Notice Over Minimum Bid Price Requirement
MT
03/09MIDATECH PHARMA : announces R&D collaboration with Janssen on a second molecule - Form 6-K
PU
03/09Midatech Pharma Extend R&D Partnership With Johnson & Johnson Unit
MT
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 9,60 M 12,1 M 12,0 M
EV / Sales -1
EV / Sales 0
Nbr of Employees 20
Free-Float 87,6%
Chart MIDATECH PHARMA PLC
Duration : Period :
Midatech Pharma plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIDATECH PHARMA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,10
Average target price
Spread / Average Target -
Managers and Directors
Stephen Anthony Stamp Director, Chief Executive & Financial Officer
Rolf Stahel Non-Executive Chairman
Dmitry Zamoryakhin Chief Scientific Officer
Dan Palmer Vice President-Technology
Sijmen de Vries Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MIDATECH PHARMA PLC-46.58%12
GILEAD SCIENCES, INC.-11.38%80 715
REGENERON PHARMACEUTICALS, INC.8.63%73 916
VERTEX PHARMACEUTICALS22.26%68 665
WUXI APPTEC CO., LTD.-22.20%40 017
BIONTECH SE-40.07%37 546